Safety of the first dose of mRNA SARS-CoV-2 vaccines in patients with rheumatic and musculoskeletal diseases

Ann Rheum Dis. 2021 Aug;80(8):1100-1101. doi: 10.1136/annrheumdis-2021-220231. Epub 2021 Mar 19.

Authors

Caoilfhionn M Connolly^#¹, Jake A Ruddy^#², Brian J Boyarsky², Robin K Avery³, William A Werbel³, Dorry L Segev^{2

4}, Jacqueline Garonzik-Wang², Julie J Paik⁵

Affiliations

¹ Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA connolly@jhmi.edu.
² Surgery, Johns Hopkins, Baltimore, Maryland, USA.
³ Infectious Diseases, Johns Hopkins University, Baltimore, Maryland, USA.
⁴ Johns Hopkins University Bloomberg School of Public Health, Baltimore, Maryland, USA.
⁵ Rheumatology, Johns Hopkins University, Baltimore, Maryland, USA.

^# Contributed equally.

No abstract available

Keywords: COVID-19; autoimmune diseases; epidemiology; vaccination.

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Letter

MeSH terms

COVID-19 Vaccines* / adverse effects
COVID-19* / prevention & control
Humans
Musculoskeletal Diseases*
Rheumatic Diseases*
SARS-CoV-2
Vaccination

Substances

COVID-19 Vaccines

Grants and funding